for males ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
completion around
Principal Investigator
by Andrew Leavitt



This Phase III clinical study will assess the impact of BMN 270 (compared to FVIII prophylaxis) on the number of bleeding episodes irrespective of exogenous FVIII replacement treatment in the efficacy evaluation period (EEP) (from Week 5 post-BMN 270 infusion (Study Day 33) or the end of FVIII prophylaxis plus the washout period (3 days for products of standard half-life or plasma-derived and 5 days for products of extended half-life), whichever is later, to last visit by the data cut-off for the 2-year analysis, hereafter referred to as "Post FVIII Prophylaxis to Last Visit"). The study will also assess the impact of BMN 270 (compared to FVIII prophylaxis) on: the number of bleeding episodes requiring exogenous FVIII treatment in "Post FVIII Prophylaxis to Last Visit", FVIII activity as measured by chromogenic sustrate assay at Week 104 following intravenous infusion of BMN 270, usage of exogenous FVIII replacement therapy in "Post FVIII Prophylaxis to Last Visit", health-related quality of life patient-reported outcomes at week 104 following intravenous infusion of BMN 270. The study will also evaluate the safety of the BMN 270.

Official Title

A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients With Residual FVIII Levels ≤ 1 IU/dL Receiving Prophylactic FVIII Infusions


Hemophilia A, Gene Therapy, Clotting Disorders, Blood Disorder, Blood Coagulation Disorders, Inherited Blood Coagulation disorders, Hematologic Diseases, Coagulation Protein Disorders, Hemorrhagic Disorders, Genetic Diseases, Inborn, Factor VIII, Coagulants, valoctocogene roxaparvovec, valoctocogene roxaparvovec Open Label


You can join if…

Open to males ages 18 years and up

  1. Males ≥ 18 years of age with hemophilia A and residual FVIII levels ≤ 1 IU/dL as evidenced by medical history, at the time of signing the informed consent.
  2. Must have been on prophylactic FVIII replacement therapy for at least 12 months prior to study entry.
  3. Treated/exposed to FVIII concentrates or cryoprecipitate for a minimum of 150 exposure days (EDs).
  4. No previous documented history of a detectable FVIII inhibitor, and results from a Bethesda assay or Bethesda assay with Nijmegen modification of less than 0.6 Bethesda Units (BU) on 2 consecutive occasions at least one week apart within the past 12 months.

You CAN'T join if...

  1. Detectable pre-existing antibodies to the adeno-associated virus 5 (AAV5) capsid.
  2. Any evidence of active infection or any immunosuppressive disorder, except for HIV infection
  3. Any evidence of active infection or any immunosuppressive disorder, including HIV infection (effective as of Protocol Amendment 3)
  4. Significant liver dysfunction.
  5. Prior liver biopsy showing significant fibrosis.
  6. Evidence of any bleeding disorder not related to hemophilia A.
  7. Platelet count of < 100 x 109/L.
  8. Creatinine ≥ 1.5 mg/dL.
  9. Liver cirrhosis of any etiology as assessed by liver ultrasound.
  10. Chronic or active hepatitis B.
  11. Active Hepatitis C.
  12. Active malignancy, except non-melanoma skin cancer.
  13. History of hepatic malignancy.
  14. History of arterial or venous thromboembolic events.
  15. Known inherited or acquired thrombophilia, including conditions associated with increased thromboembolic risk, such as atrial fibrillation.


  • UCSF Medical Center
    San Francisco California 94143-0106 United States
  • UC Davis Hemophilia Treatment Center
    Sacramento California 95817 United States

Lead Scientist at UCSF


in progress, not accepting new patients
Start Date
Completion Date
BioMarin Pharmaceutical
Phase 3 Hemophilia Research Study
Study Type
About 144 people participating
Last Updated